JP2017537629A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017537629A5 JP2017537629A5 JP2017529741A JP2017529741A JP2017537629A5 JP 2017537629 A5 JP2017537629 A5 JP 2017537629A5 JP 2017529741 A JP2017529741 A JP 2017529741A JP 2017529741 A JP2017529741 A JP 2017529741A JP 2017537629 A5 JP2017537629 A5 JP 2017537629A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- set forth
- chain variable
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001413 amino acids Chemical class 0.000 claims description 1158
- 230000004048 modification Effects 0.000 claims description 404
- 238000012986 modification Methods 0.000 claims description 404
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 220
- 239000000427 antigen Substances 0.000 claims description 172
- 102000036639 antigens Human genes 0.000 claims description 172
- 108091007433 antigens Proteins 0.000 claims description 172
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 80
- 229920001184 polypeptide Polymers 0.000 claims description 76
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 76
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 56
- 150000007523 nucleic acids Chemical class 0.000 claims description 48
- 108020004707 nucleic acids Proteins 0.000 claims description 46
- 102000039446 nucleic acids Human genes 0.000 claims description 46
- 210000004027 cell Anatomy 0.000 claims description 44
- 206010028980 Neoplasm Diseases 0.000 claims description 34
- 230000009826 neoplastic cell growth Effects 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 21
- 208000034578 Multiple myelomas Diseases 0.000 claims description 20
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 20
- 230000011664 signaling Effects 0.000 claims description 16
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 14
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 14
- 230000000139 costimulatory effect Effects 0.000 claims description 14
- 102100021197 G-protein coupled receptor family C group 5 member D Human genes 0.000 claims description 12
- 230000003834 intracellular effect Effects 0.000 claims description 12
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 claims description 10
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 claims description 10
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 10
- 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 claims description 9
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims description 9
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 8
- 101001040713 Homo sapiens G-protein coupled receptor family C group 5 member D Proteins 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 102000004127 Cytokines Human genes 0.000 claims description 6
- 108090000695 Cytokines Proteins 0.000 claims description 6
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 6
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 6
- 239000003446 ligand Substances 0.000 claims description 6
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims description 4
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 4
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims description 4
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 4
- 101710174800 G-protein coupled receptor family C group 5 member D Proteins 0.000 claims description 4
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims description 4
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 4
- 230000028993 immune response Effects 0.000 claims description 4
- 210000001778 pluripotent stem cell Anatomy 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 230000004083 survival effect Effects 0.000 claims description 3
- 210000004881 tumor cell Anatomy 0.000 claims description 3
- 108010082808 4-1BB Ligand Proteins 0.000 claims description 2
- 102100036008 CD48 antigen Human genes 0.000 claims description 2
- 102100025221 CD70 antigen Human genes 0.000 claims description 2
- -1 CD86 Proteins 0.000 claims description 2
- 101000716130 Homo sapiens CD48 antigen Proteins 0.000 claims description 2
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 claims description 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims description 2
- 101000648507 Homo sapiens Tumor necrosis factor receptor superfamily member 14 Proteins 0.000 claims description 2
- 108090000177 Interleukin-11 Proteins 0.000 claims description 2
- 108010065805 Interleukin-12 Proteins 0.000 claims description 2
- 108090000172 Interleukin-15 Proteins 0.000 claims description 2
- 108050003558 Interleukin-17 Proteins 0.000 claims description 2
- 108010002350 Interleukin-2 Proteins 0.000 claims description 2
- 108010002386 Interleukin-3 Proteins 0.000 claims description 2
- 108090001005 Interleukin-6 Proteins 0.000 claims description 2
- 108010002586 Interleukin-7 Proteins 0.000 claims description 2
- 102000017578 LAG3 Human genes 0.000 claims description 2
- 101150030213 Lag3 gene Proteins 0.000 claims description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 2
- 108010042215 OX40 Ligand Proteins 0.000 claims description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 2
- 101100225046 Schizosaccharomyces pombe (strain 972 / ATCC 24843) ecl2 gene Proteins 0.000 claims description 2
- 101100225047 Schizosaccharomyces pombe (strain 972 / ATCC 24843) ecl3 gene Proteins 0.000 claims description 2
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims description 2
- 102100026890 Tumor necrosis factor ligand superfamily member 4 Human genes 0.000 claims description 2
- 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 claims description 2
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims description 2
- 101150058725 ecl1 gene Proteins 0.000 claims description 2
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims description 2
- 108020001507 fusion proteins Proteins 0.000 claims description 2
- 102000037865 fusion proteins Human genes 0.000 claims description 2
- 108010074108 interleukin-21 Proteins 0.000 claims description 2
- 210000004698 lymphocyte Anatomy 0.000 claims description 2
- 210000003738 lymphoid progenitor cell Anatomy 0.000 claims description 2
- 210000004897 n-terminal region Anatomy 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 210000003289 regulatory T cell Anatomy 0.000 claims description 2
- 210000000130 stem cell Anatomy 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 14
- 230000004043 responsiveness Effects 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462088286P | 2014-12-05 | 2014-12-05 | |
| US62/088,286 | 2014-12-05 | ||
| PCT/US2015/064102 WO2016090312A1 (en) | 2014-12-05 | 2015-12-04 | Chimeric antigen receptors targeting g-protein coupled receptor and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020198690A Division JP2021040652A (ja) | 2014-12-05 | 2020-11-30 | Ｇタンパク質共役受容体を標的化するキメラ抗原受容体およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017537629A JP2017537629A (ja) | 2017-12-21 |
| JP2017537629A5 true JP2017537629A5 (Direct) | 2019-01-17 |
| JP6919091B2 JP6919091B2 (ja) | 2021-08-18 |
Family
ID=56092565
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017529741A Active JP6919091B2 (ja) | 2014-12-05 | 2015-12-04 | Ｇタンパク質共役受容体を標的化するキメラ抗原受容体およびその使用 |
| JP2020198690A Withdrawn JP2021040652A (ja) | 2014-12-05 | 2020-11-30 | Ｇタンパク質共役受容体を標的化するキメラ抗原受容体およびその使用 |
| JP2023079310A Withdrawn JP2023091037A (ja) | 2014-12-05 | 2023-05-12 | Ｇタンパク質共役受容体を標的化するキメラ抗原受容体およびその使用 |
| JP2025156538A Pending JP2025181929A (ja) | 2014-12-05 | 2025-09-19 | Ｇタンパク質共役受容体を標的化するキメラ抗原受容体およびその使用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020198690A Withdrawn JP2021040652A (ja) | 2014-12-05 | 2020-11-30 | Ｇタンパク質共役受容体を標的化するキメラ抗原受容体およびその使用 |
| JP2023079310A Withdrawn JP2023091037A (ja) | 2014-12-05 | 2023-05-12 | Ｇタンパク質共役受容体を標的化するキメラ抗原受容体およびその使用 |
| JP2025156538A Pending JP2025181929A (ja) | 2014-12-05 | 2025-09-19 | Ｇタンパク質共役受容体を標的化するキメラ抗原受容体およびその使用 |
Country Status (26)
| Country | Link |
|---|---|
| US (5) | US10633426B2 (Direct) |
| EP (2) | EP3227339B1 (Direct) |
| JP (4) | JP6919091B2 (Direct) |
| KR (1) | KR102612367B1 (Direct) |
| CN (4) | CN113968912B (Direct) |
| AU (2) | AU2015357518B2 (Direct) |
| CA (1) | CA2969864A1 (Direct) |
| CY (1) | CY1125008T1 (Direct) |
| DK (1) | DK3227339T3 (Direct) |
| ES (1) | ES2899779T3 (Direct) |
| HR (1) | HRP20211978T1 (Direct) |
| HU (1) | HUE057777T2 (Direct) |
| IL (2) | IL310130A (Direct) |
| LT (1) | LT3227339T (Direct) |
| MX (2) | MX385156B (Direct) |
| MY (1) | MY192065A (Direct) |
| PH (1) | PH12017501044A1 (Direct) |
| PL (1) | PL3227339T3 (Direct) |
| PT (1) | PT3227339T (Direct) |
| RS (1) | RS62870B1 (Direct) |
| RU (1) | RU2762359C2 (Direct) |
| SA (1) | SA517381665B1 (Direct) |
| SG (2) | SG10202007326QA (Direct) |
| SI (1) | SI3227339T1 (Direct) |
| SM (1) | SMT202200040T1 (Direct) |
| WO (1) | WO2016090312A1 (Direct) |
Families Citing this family (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201913937QA (en) * | 2014-12-05 | 2020-03-30 | Memorial Sloan Kettering Cancer Center | Antibodies targeting g-protein coupled receptor and methods of use |
| EP3227339B1 (en) | 2014-12-05 | 2021-11-10 | Memorial Sloan-Kettering Cancer Center | Chimeric antigen receptors targeting g-protein coupled receptor and uses thereof |
| EP3466967A1 (en) | 2015-05-18 | 2019-04-10 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| US20190233533A1 (en) | 2016-06-28 | 2019-08-01 | Umc Utrecht Holding B.V. | Treatment Of IgE-Mediated Diseases With Antibodies That Specifically Bind CD38 |
| US11242376B2 (en) | 2016-08-02 | 2022-02-08 | TCR2 Therapeutics Inc. | Compositions and methods for TCR reprogramming using fusion proteins |
| KR102048477B1 (ko) * | 2016-08-05 | 2019-11-26 | 주식회사 와이바이오로직스 | 프로그램화된 세포 사멸 단백질 리간드-1 (pd-l1)에 대한 항체 및 이의 용도 |
| GB2564823B8 (en) | 2016-10-07 | 2022-06-29 | Tcr2 Therapeutics Inc | Compositions and methods for TCR reprogramming using fusion proteins |
| CA3044593A1 (en) | 2016-11-22 | 2018-05-31 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| CN110352068A (zh) | 2016-12-02 | 2019-10-18 | 南加利福尼亚大学 | 合成的免疫受体及其使用方法 |
| AU2018205888B2 (en) | 2017-01-05 | 2021-09-02 | Kahr Medical Ltd. | A PD1-41BBL fusion protein and methods of use thereof |
| US11299530B2 (en) | 2017-01-05 | 2022-04-12 | Kahr Medical Ltd. | SIRP alpha-CD70 fusion protein and methods of use thereof |
| PL3565828T3 (pl) | 2017-01-05 | 2022-04-04 | Kahr Medical Ltd. | Białko fuzyjne SIRP1 ALFA-41BBL i sposoby jego zastosowania |
| WO2018127916A1 (en) | 2017-01-05 | 2018-07-12 | Kahr Medical Ltd. | A pd1-cd70 fusion protein and methods of use thereof |
| CN110462038A (zh) * | 2017-02-07 | 2019-11-15 | 第一三共株式会社 | 抗gprc5d抗体和包含所述抗体的分子 |
| JP2020517287A (ja) | 2017-04-26 | 2020-06-18 | ユーリカ セラピューティックス， インコーポレイテッド | キメラ抗体／ｔ細胞受容体構築物及びその使用 |
| BR112020001605A2 (pt) | 2017-08-09 | 2020-08-11 | Juno Therapeutics Inc | métodos para produzir composições de células geneticamente modificadas e composições relacionadas |
| MA49981A (fr) | 2017-08-09 | 2020-06-17 | Juno Therapeutics Inc | Procédés et compositions de préparation de cellules génétiquement modifiées |
| EP3679370A1 (en) | 2017-09-07 | 2020-07-15 | Juno Therapeutics, Inc. | Methods of identifying cellular attributes related to outcomes associated with cell therapy |
| US12258580B2 (en) | 2017-11-01 | 2025-03-25 | Juno Therapeutics, Inc. | Process for generating therapeutic compositions of engineered cells |
| US12031975B2 (en) | 2017-11-01 | 2024-07-09 | Juno Therapeutics, Inc. | Methods of assessing or monitoring a response to a cell therapy |
| CA3080904A1 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for b-cell maturation antigen |
| BR112020008565A2 (pt) | 2017-11-01 | 2020-10-20 | Juno Therapeutics Inc | processo para a produção de uma composição de célula t |
| WO2019089848A1 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Methods associated with tumor burden for assessing response to a cell therapy |
| JP7447006B2 (ja) | 2017-11-01 | 2024-03-11 | ジュノー セラピューティクス インコーポレイテッド | Ｂ細胞成熟抗原（ｂｃｍａ）に特異的なキメラ抗原受容体 |
| CA3082570A1 (en) | 2017-11-14 | 2019-05-23 | Memorial Sloan-Kettering Cancer Center | Il-36 secreting immunoresponsive cells and uses thereof |
| EP3716980A1 (en) | 2017-12-01 | 2020-10-07 | Juno Therapeutics, Inc. | Methods for dosing and for modulation of genetically engineered cells |
| BR112020011223A2 (pt) | 2017-12-08 | 2020-11-17 | Juno Therapeutics Inc | marcadores fenotípicos para terapia celular e mé-todos relacionados |
| MX2020005908A (es) | 2017-12-08 | 2020-10-07 | Juno Therapeutics Inc | Proceso para producir una composicion de celulas t modificadas. |
| MA51105A (fr) | 2017-12-08 | 2020-10-14 | Juno Therapeutics Inc | Formulation de milieux sans sérum pour la culture de cellules et ses procédés d'utilisation |
| KR20200136473A (ko) * | 2018-03-30 | 2020-12-07 | 유레카 쎄라퓨틱스, 인코포레이티드 | Cd22를 표적으로 하는 구축물 및 이의 용도 |
| CN120285175A (zh) | 2018-05-16 | 2025-07-11 | 詹森生物科技公司 | 治疗癌症并增强t细胞重定向治疗剂的功效的方法 |
| US12286466B2 (en) | 2018-07-11 | 2025-04-29 | Kahr Medical Ltd. | PD1-4-1BBL variant fusion protein and methods of use thereof |
| CA3104780A1 (en) | 2018-07-11 | 2020-01-16 | Kahr Medical Ltd. | Sirpalpha-4-1bbl variant fusion protein and methods of use thereof |
| BR112021002245A2 (pt) | 2018-08-09 | 2021-05-04 | Juno Therapeutics Inc | métodos para avaliar ácidos nucleicos integrados |
| IL280659B2 (en) | 2018-08-09 | 2024-11-01 | Juno Therapeutics Inc | Processes for generating engineered cells and compositions thereof |
| WO2020081988A1 (en) * | 2018-10-19 | 2020-04-23 | Memorial Sloan-Kettering Cancer Center | Chimeric antigen receptor targeting sialyl lewis a and uses thereof |
| EP3874024A1 (en) | 2018-10-31 | 2021-09-08 | Juno Therapeutics GmbH | Methods for selection and stimulation of cells and apparatus for same |
| EP3873937A2 (en) * | 2018-11-01 | 2021-09-08 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for g protein-coupled receptor class c group 5 member d (gprc5d) |
| WO2020092848A2 (en) | 2018-11-01 | 2020-05-07 | Juno Therapeutics, Inc. | Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen |
| MX2021006238A (es) | 2018-11-30 | 2021-10-01 | Juno Therapeutics Inc | Metodos para tratamiento que usan terapia celular adoptiva. |
| CA3127025A1 (en) * | 2019-01-18 | 2020-07-23 | Janssen Biotech, Inc. | Gprc5d chimeric antigen receptors and cells expressing the same |
| MX2021013219A (es) | 2019-05-01 | 2022-02-17 | Juno Therapeutics Inc | Celulas que expresan un receptor recombinante de un locus de tgfbr2 modificado, polinucleotidos relacionados y metodos. |
| SG11202111372VA (en) | 2019-05-01 | 2021-11-29 | Juno Therapeutics Inc | Cells expressing a chimeric receptor from a modified cd247 locus, related polynucleotides and methods |
| JP2022537700A (ja) | 2019-06-12 | 2022-08-29 | ジュノー セラピューティクス インコーポレイテッド | 細胞媒介細胞傷害性療法と生存促進性ｂｃｌ２ファミリータンパク質の阻害剤との併用療法 |
| US20220298222A1 (en) | 2019-08-22 | 2022-09-22 | Juno Therapeutics, Inc. | Combination therapy of a t cell therapy and an enhancer of zeste homolog 2 (ezh2) inhibitor and related methods |
| BR112022003553A2 (pt) | 2019-08-30 | 2022-05-24 | Allogene Therapeutics Inc | Receptores de citocina quiméricos compreendendo domínios de ligação a tgf beta |
| BR112022008023A2 (pt) | 2019-10-30 | 2022-07-12 | Juno Therapeutics Gmbh | Dispositivos de seleção e/ou estimulação de células e métodos de uso |
| US10980836B1 (en) | 2019-12-11 | 2021-04-20 | Myeloid Therapeutics, Inc. | Therapeutic cell compositions and methods of manufacturing and use thereof |
| WO2021154887A1 (en) | 2020-01-28 | 2021-08-05 | Juno Therapeutics, Inc. | Methods for t cell transduction |
| CN116096412A (zh) | 2020-04-10 | 2023-05-09 | 因维德公司 | 对冠状病毒s蛋白质具有特异性的化合物及其用途 |
| US20230178239A1 (en) | 2020-05-13 | 2023-06-08 | Juno Therapeutics, Inc. | Methods of identifying features associated with clinical response and uses thereof |
| JP2023531531A (ja) | 2020-06-26 | 2023-07-24 | ジュノ セラピューティクス ゲーエムベーハー | 組換え受容体を条件付きで発現する操作されたｔ細胞、関連ポリヌクレオチド、および方法 |
| JP2023549780A (ja) | 2020-11-04 | 2023-11-29 | ジュノー セラピューティクス インコーポレイテッド | 改変されたインバリアントｃｄ３免疫グロブリンスーパーファミリー鎖遺伝子座からキメラ受容体を発現する細胞ならびに関連するポリヌクレオチドおよび方法 |
| WO2022133169A1 (en) | 2020-12-18 | 2022-06-23 | Century Therapeutics, Inc. | Chimeric antigen receptor systems with adaptable receptor specificity |
| WO2022148370A1 (en) * | 2021-01-05 | 2022-07-14 | Lanova Medicines Development Co., Ltd. | Anti-gprc5d monoclonal antibodies and uses thereof |
| JP2024509853A (ja) | 2021-03-03 | 2024-03-05 | ジュノー セラピューティクス インコーポレイテッド | Ｔ細胞療法およびｄｇｋ阻害剤の組合せ |
| IL305950A (en) | 2021-03-17 | 2023-11-01 | Myeloid Therapeutics Inc | Engineered chimeric fusion protein compositions and methods of using them |
| KR20230158573A (ko) | 2021-03-22 | 2023-11-20 | 주노 쎄러퓨티크스 인코퍼레이티드 | 바이러스 벡터 입자의 효력을 평가하는 방법 |
| AU2022241654A1 (en) | 2021-03-22 | 2023-09-28 | Juno Therapeutics, Inc. | Methods of determining potency of a therapeutic cell composition |
| CN116964100A (zh) * | 2021-04-07 | 2023-10-27 | 株式会社Lg化学 | Gucy2c结合多肽及其用途 |
| US20250283037A1 (en) | 2021-05-06 | 2025-09-11 | Juno Therapeutics Gmbh | Methods for stimulating and transducing t cells |
| CN115386010B (zh) * | 2021-05-23 | 2026-02-06 | 上海邦耀生物科技有限公司 | 靶向gprc5d的嵌合抗原受体及其用途 |
| JP2024534847A (ja) | 2021-08-30 | 2024-09-26 | オリセル セラピューティクス カンパニー リミテッド | 抗ｇｐｒｃ５ｄ抗原結合タンパク質とその使用 |
| WO2023079494A1 (en) | 2021-11-03 | 2023-05-11 | Janssen Biotech, Inc. | Corticosteriod reduction in treatment with anti-cd38 antibodies |
| EP4497759A4 (en) | 2022-01-14 | 2026-02-11 | Oricell Therapeutics Co Ltd | CHIMERIC ANTIGENIC RECEPTOR TARGETING GPRC5D AND ITS APPLICATION |
| JP2025504002A (ja) | 2022-01-28 | 2025-02-06 | ジュノー セラピューティクス インコーポレイテッド | 細胞組成物を製造する方法 |
| KR20240137090A (ko) | 2022-01-29 | 2024-09-19 | 카스젠 라이프 사이언스 씨오., 엘티디. | Gprc5d 항체 및 그 용도 |
| US20250297282A1 (en) | 2022-05-05 | 2025-09-25 | Juno Therapeutics Gmbh | Viral-binding protein and related reagents, articles, and methods of use |
| WO2023220655A1 (en) | 2022-05-11 | 2023-11-16 | Celgene Corporation | Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy |
| IL316839A (en) | 2022-05-17 | 2025-01-01 | Umoja Biopharma Inc | Production of viral particles |
| WO2023230581A1 (en) | 2022-05-25 | 2023-11-30 | Celgene Corporation | Methods of manufacturing t cell therapies |
| JP2025524373A (ja) | 2022-06-10 | 2025-07-30 | ウモジャ バイオファーマ インコーポレイテッド | 操作された幹細胞およびその使用 |
| US20250177530A1 (en) * | 2022-06-24 | 2025-06-05 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Molecules that bind to enpp1 polypeptides |
| CN120051297A (zh) | 2022-06-30 | 2025-05-27 | 因达普塔治疗公司 | 工程化自然杀伤(nk)细胞与抗体疗法的组合及相关方法 |
| CA3263560A1 (en) | 2022-08-05 | 2024-02-08 | Juno Therapeutics, Inc. | GPRC5D AND BCMA SPECIFIC CHIMERICAL ANTIGENIC RECEPTORS |
| CN116003598B (zh) | 2022-08-30 | 2024-04-26 | 苏州缔码生物科技有限公司 | 靶向人gprc5d的重组人源化单克隆抗体及其应用 |
| CN120152717A (zh) | 2022-09-08 | 2025-06-13 | 朱诺治疗学股份有限公司 | T细胞疗法和连续或间歇dgk抑制剂给药的组合 |
| WO2024097992A2 (en) | 2022-11-04 | 2024-05-10 | Umoja Biopharma, Inc. | Particles displaying adhesion-molecule fusions |
| EP4615960A1 (en) | 2022-11-09 | 2025-09-17 | C3S2 GmbH | Methods for manufacturing engineered immune cells |
| WO2024102954A1 (en) | 2022-11-10 | 2024-05-16 | Massachusetts Institute Of Technology | Activation induced clipping system (aics) |
| JP2026504491A (ja) | 2023-02-03 | 2026-02-05 | ツェー３エス２ ゲーエムベーハー | 操作された免疫細胞の非ウイルス的製造のための方法 |
| KR20250169631A (ko) | 2023-04-18 | 2025-12-03 | 주노 쎄러퓨티크스 인코퍼레이티드 | 치료 세포 조성물의 효력을 평가하기 위한 세포독성 검정 |
| WO2024243365A2 (en) | 2023-05-23 | 2024-11-28 | Juno Therapeutics, Inc. | Activation markers of t cells and method for assessing t cell activation |
| EP4520346A1 (en) * | 2023-09-06 | 2025-03-12 | Gyncentrum Sp. z o.o. | Cells, methods and systems for use in the treatment of a cancer with dual-car-t |
| WO2025059362A1 (en) | 2023-09-13 | 2025-03-20 | Juno Therapeutics, Inc. | Combination therapies with a cell therapy expressing a gprc5d-targeting car and related methods and uses |
| WO2025076472A1 (en) | 2023-10-06 | 2025-04-10 | Juno Therapeutics, Inc. | Combination therapies with a cell therapy expressing a gprc5d-targeting car and related methods and uses |
| CN120005019A (zh) * | 2023-11-14 | 2025-05-16 | 成都优赛诺生物科技有限公司 | 一种靶向gprc5d的单域抗体、嵌合抗原受体及其应用 |
| WO2025129084A1 (en) | 2023-12-13 | 2025-06-19 | Umoja Biopharma, Inc. | Engineered induced stem cell derived myeloid cells and methods of differentiating and using same |
| WO2025147545A1 (en) | 2024-01-03 | 2025-07-10 | Juno Therapeutics, Inc. | Lipid nanoparticles for delivery of nucleic acids and related methods and uses |
| WO2025231174A1 (en) | 2024-04-30 | 2025-11-06 | Umoja Biopharma, Inc. | Manufacturing viral particles |
| WO2025231372A2 (en) | 2024-05-03 | 2025-11-06 | Janssen Biotech, Inc. | Methods for treating multiple myeloma with car-t cells and bispecific antibodies |
| US20260041768A1 (en) | 2024-05-03 | 2026-02-12 | Janssen Biotech, Inc. | Methods for treating multiple myeloma with car-t cells and bispecific antibodies |
| WO2025235604A1 (en) | 2024-05-08 | 2025-11-13 | Umoja Biopharma, Inc. | Fusion protein for use as immune cell engager |
| WO2026020055A2 (en) | 2024-07-18 | 2026-01-22 | Juno Therapeutics, Inc. | Methods for assessing exosomes in a cell composition and related uses |
| WO2026025092A1 (en) | 2024-07-26 | 2026-01-29 | Juno Therapeutics, Inc. | Synthetic promoters for t cell expression |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| JPS6412935A (en) | 1987-07-02 | 1989-01-17 | Mitsubishi Electric Corp | Constant-speed travel device for vehicle |
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| US6436703B1 (en) | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
| KR20120053525A (ko) | 2000-06-16 | 2012-05-25 | 캠브리지 안티바디 테크놀로지 리미티드 | 면역특이적으로 ＢＬｙＳ에 결합하는 항체 |
| US20030207288A1 (en) | 2001-08-20 | 2003-11-06 | Lewin David A. | GPCR-like retinoic acid-induced gene 1 protein and nucleic acid |
| EP1468694A1 (en) * | 2001-12-27 | 2004-10-20 | Sumitomo Pharmaceuticals Company, Limited | Remedies for anorexia or lifestyle-related diseases and method of screening the same |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| US20040110139A1 (en) * | 2002-12-10 | 2004-06-10 | Isis Pharmaceuticals Inc. | Modulation of G protein-coupled receptor 3 expression |
| ES2388280T3 (es) | 2002-12-20 | 2012-10-11 | Abbott Biotherapeutics Corp. | Anticuerpos que reaccionan frente a GPR64 y utilización de los mismos |
| EP1592713A2 (en) | 2003-02-13 | 2005-11-09 | Pharmacia Corporation | Antibodies to c-met for the treatment of cancers |
| WO2005019258A2 (en) | 2003-08-11 | 2005-03-03 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| BRPI0417429A (pt) * | 2003-12-10 | 2007-04-03 | Medarex Inc | anticorpo monoclonal isolado ou uma porção de ligação de antìgeno deste, composição, imunoconjugado, molécula biespecìfica, vetor de expressão, célula hospedeira, camundongo transgênico, hibridoma, e, métodos de inibir uma resposta inflamatória ou autoimune, de tratar uma doença inflamatória ou autoimune, de tratar uma infecção viral ou bacteriana e de preparar um anticorpo anti-ip-10 |
| US20050266008A1 (en) * | 2004-03-29 | 2005-12-01 | Medarex, Inc. | Human anti-IRTA-5 antibodies |
| TW200815474A (en) | 2006-08-03 | 2008-04-01 | Astrazeneca Ab | Antibodies alphaVbeta6 and uses thereof |
| US9512236B2 (en) | 2006-12-19 | 2016-12-06 | Ablynx N.V. | Amino acid sequences directed against GPCRS and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders |
| PT2856876T (pt) | 2007-03-30 | 2018-03-28 | Memorial Sloan Kettering Cancer Center | Expressão constitutiva de ligantes co-estimulatórios em linfócitos t adotivamente transferidos |
| EP2192922A4 (en) | 2007-09-17 | 2010-09-29 | Univ California | INTERNATIONALIZING HUMAN MONOCLONAL ANTIBODIES TO PROMOTE IN SITU ON PROSTATAZELLES |
| WO2009051633A1 (en) | 2007-10-15 | 2009-04-23 | The Board Of Trustees Of The Leland Stanford Junior University | Gpcr crystalization method using an antibody |
| MX2010004482A (es) * | 2007-10-25 | 2010-07-06 | Trellis Bioscience Inc | Anticuerpos anti-proteina g vsr. |
| ES2639857T3 (es) | 2008-02-11 | 2017-10-30 | Cure Tech Ltd. | Anticuerpos monoclonales para el tratamiento del tumor |
| US9217032B2 (en) | 2010-01-08 | 2015-12-22 | Les Laboratoires Servier | Methods for treating colorectal cancer |
| WO2012009790A1 (en) | 2010-07-22 | 2012-01-26 | Schrader John W | Cross-protective pathogen protection, methods and compositions thereof |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| US9833476B2 (en) * | 2011-08-31 | 2017-12-05 | The Trustees Of Dartmouth College | NKP30 receptor targeted therapeutics |
| CN103483452B (zh) * | 2012-06-12 | 2021-08-13 | 上海细胞治疗集团有限公司 | 双信号独立的嵌合抗原受体及其用途 |
| WO2014087010A1 (en) | 2012-12-07 | 2014-06-12 | Ablynx N.V. | IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE |
| JO3519B1 (ar) | 2013-01-25 | 2020-07-05 | Amgen Inc | تركيبات أجسام مضادة لأجل cdh19 و cd3 |
| ES2653487T3 (es) * | 2013-02-15 | 2018-02-07 | The Regents Of The University Of California | Receptor de antígeno quimérico y métodos de uso del mismo |
| EP2970426B1 (en) * | 2013-03-15 | 2019-08-28 | Michael C. Milone | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| ES2645393T3 (es) | 2013-05-29 | 2017-12-05 | Cellectis | Métodos de manipulación de linfocitos T para inmunoterapia usando el sistema de nucleasa Cas guiada por ARN |
| WO2015142675A2 (en) | 2014-03-15 | 2015-09-24 | Novartis Ag | Treatment of cancer using chimeric antigen receptor |
| EP3164417A1 (en) | 2014-07-01 | 2017-05-10 | Pfizer Inc. | Bispecific heterodimeric diabodies and uses thereof |
| WO2016014530A1 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Combinations of low, immune enhancing. doses of mtor inhibitors and cars |
| SG10201913937QA (en) | 2014-12-05 | 2020-03-30 | Memorial Sloan Kettering Cancer Center | Antibodies targeting g-protein coupled receptor and methods of use |
| EP3227339B1 (en) | 2014-12-05 | 2021-11-10 | Memorial Sloan-Kettering Cancer Center | Chimeric antigen receptors targeting g-protein coupled receptor and uses thereof |
| EP3365364B1 (en) | 2015-10-23 | 2024-04-10 | Eureka Therapeutics, Inc. | Antibody/t-cell receptor chimeric constructs and uses thereof |
| MY197441A (en) | 2015-12-04 | 2023-06-19 | Memorial Sloan Kettering Cancer Center | Antibodies targeting fc receptor-like 5 and method of use |
| CN109715207B (zh) | 2016-03-29 | 2023-03-31 | 南加利福尼亚大学 | 靶向癌症的嵌合抗原受体 |
| US11768203B2 (en) | 2016-03-31 | 2023-09-26 | University Of Southern California | Highly sensitive and specific luciferase based reporter assay for antigen detection |
| CN108239144B (zh) | 2018-01-26 | 2021-05-25 | 重庆精准生物技术有限公司 | 改造的铰链及其在构建car骨架中的应用 |
| EP3873937A2 (en) | 2018-11-01 | 2021-09-08 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for g protein-coupled receptor class c group 5 member d (gprc5d) |
-
2015
- 2015-12-04 EP EP15865633.0A patent/EP3227339B1/en active Active
- 2015-12-04 DK DK15865633.0T patent/DK3227339T3/da active
- 2015-12-04 WO PCT/US2015/064102 patent/WO2016090312A1/en not_active Ceased
- 2015-12-04 RS RS20211596A patent/RS62870B1/sr unknown
- 2015-12-04 PL PL15865633T patent/PL3227339T3/pl unknown
- 2015-12-04 MY MYPI2017000855A patent/MY192065A/en unknown
- 2015-12-04 PT PT158656330T patent/PT3227339T/pt unknown
- 2015-12-04 MX MX2017007242A patent/MX385156B/es unknown
- 2015-12-04 KR KR1020177018389A patent/KR102612367B1/ko active Active
- 2015-12-04 CN CN202111119531.9A patent/CN113968912B/zh active Active
- 2015-12-04 ES ES15865633T patent/ES2899779T3/es active Active
- 2015-12-04 SM SM20220040T patent/SMT202200040T1/it unknown
- 2015-12-04 LT LTEPPCT/US2015/064102T patent/LT3227339T/lt unknown
- 2015-12-04 SG SG10202007326QA patent/SG10202007326QA/en unknown
- 2015-12-04 AU AU2015357518A patent/AU2015357518B2/en active Active
- 2015-12-04 CN CN202410434671.2A patent/CN118271463A/zh active Pending
- 2015-12-04 SG SG11201704547RA patent/SG11201704547RA/en unknown
- 2015-12-04 HU HUE15865633A patent/HUE057777T2/hu unknown
- 2015-12-04 HR HRP20211978TT patent/HRP20211978T1/hr unknown
- 2015-12-04 CA CA2969864A patent/CA2969864A1/en active Pending
- 2015-12-04 RU RU2017123551A patent/RU2762359C2/ru active
- 2015-12-04 JP JP2017529741A patent/JP6919091B2/ja active Active
- 2015-12-04 CN CN202111126092.4A patent/CN113683711A/zh active Pending
- 2015-12-04 IL IL310130A patent/IL310130A/en unknown
- 2015-12-04 EP EP21201788.3A patent/EP4015534A1/en active Pending
- 2015-12-04 CN CN201580075557.4A patent/CN107428829B/zh active Active
- 2015-12-04 IL IL252621A patent/IL252621B2/en unknown
- 2015-12-04 SI SI201531772T patent/SI3227339T1/sl unknown
-
2017
- 2017-06-05 US US15/613,800 patent/US10633426B2/en active Active
- 2017-06-05 PH PH12017501044A patent/PH12017501044A1/en unknown
- 2017-06-05 MX MX2021008798A patent/MX2021008798A/es unknown
- 2017-06-05 SA SA517381665A patent/SA517381665B1/ar unknown
-
2020
- 2020-02-21 US US16/798,151 patent/US10906956B2/en active Active
- 2020-02-21 US US16/798,059 patent/US11820806B2/en active Active
- 2020-02-21 US US16/798,104 patent/US11866478B2/en active Active
- 2020-11-30 JP JP2020198690A patent/JP2021040652A/ja not_active Withdrawn
-
2022
- 2022-01-06 AU AU2022200052A patent/AU2022200052A1/en not_active Abandoned
- 2022-02-07 CY CY20221100105T patent/CY1125008T1/el unknown
-
2023
- 2023-05-12 JP JP2023079310A patent/JP2023091037A/ja not_active Withdrawn
- 2023-11-22 US US18/517,766 patent/US20240294599A1/en active Pending
-
2025
- 2025-09-19 JP JP2025156538A patent/JP2025181929A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017537629A5 (Direct) | ||
| JP2017537925A5 (Direct) | ||
| RU2017123551A (ru) | Химерные антигенные рецепторы, нацеленные на рецептор, связанный с g-белками, и их применение | |
| RU2017123548A (ru) | Химерные антигенные рецепторы, нацеленные на антиген созревания в-клеток, и их применение | |
| JP2018504094A5 (Direct) | ||
| JP7267921B2 (ja) | プログラム細胞死（ｐｄ－１）に対するシングルドメイン抗体 | |
| US12421292B2 (en) | Anti-DLL3 chimeric antigen receptors and uses thereof | |
| US11951172B2 (en) | Therapeutic molecules that bind to LAG3 and PD1 | |
| AU2018363291A1 (en) | Single domain antibodies that bind to CD137 | |
| JP2017524367A5 (Direct) | ||
| JP2021519072A (ja) | ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法 | |
| EP3227436A1 (en) | Chimeric antigen receptors targeting fc receptor-like 5 and uses thereof | |
| HRP20241057T1 (hr) | Kimerni antigenski receptori na osnovu jedno-domenskih antitijela i načini njihove uporabe | |
| JP2016520074A5 (Direct) | ||
| EP3969474A1 (en) | Binding molecules | |
| JPWO2021016585A5 (Direct) | ||
| JPWO2020081988A5 (Direct) | ||
| CA2974434C (en) | Chimeric antigen receptors targeting fc receptor-like 5 and uses thereof | |
| RU2020123705A (ru) | Композиции vcar и способы применения | |
| RU2022123916A (ru) | Клетки, экспрессирующие химерные активирующие рецепторы и химерные стимулирующие рецепторы, и их применение | |
| NZ732574B2 (en) | Chimeric antigen receptors targeting g-protein coupled receptor and uses thereof | |
| HK40001773A (en) | Chimeric antigen receptors targeting fc receptor-like 5 and uses thereof |